Inflammation of actinic keratoses after docetaxel

Inflammation des kératoses actiniques sous docétaxel

The occurrence of local inflammation at the side of actinic keratosis (AK) after systemic chemotherapy is not frequently reported [1]. It has mainly been described with 5-fluorouracil. We report on a case that occurred after docetaxel alone.

**Observation**

An 81 year-old man with advanced hormone-refractory prostate cancer was referred for an acute cutaneous eruption of the face and upper part of the body after initiation of docetaxel biweekly. In 2001, the patient was diagnosed with prostate adenocarcinoma (stage T2b, Gleason score 7) submitted to prostatectomy. He was then treated by bicalutamide and leuprorelin acetate. In May 2017, he was found metastatic lesions in the kidney and bones and initiated biweekly docetaxel 50 mg/m² with dexamethasone as premedication 7,5 mg as priorly reported [2] in association with denosumab. A rash appeared rapidly after the first docetaxel infusion with erythematous scaly lesions on the upper part of the body, the face and the upper trunk. Symptoms worsened after every session, so that after the 6th cycle, he was seen for diagnosis and management. At presentation, the patient presented with round and oval, 1 to 2 centimeters, macula and patches distributed on the forehead, cheeks, and nose (figure 1A) but also the upper trunk (figure 1B), shoulders and upper back (figure 1C). The lesions were asymptomatic, neither itchy, or painful, slightly scaly and rough to the touch. The underlying affected skin featured clear signs of chronic sun exposure (helioderma). The scalp was devoid of any lesion. The clinical presentation was evocative of inflamed AK. Differential diagnosis at consultation included subacute cutaneous lupus. The patient did not recall any skin lesions prior to this eruption. Physical examination was otherwise unremarkable. A 3-mm punch skin biopsy of a lesion of the upper back was performed and confirmed the diagnosis of AK (figure 2). Highly potent (betamethasone) and mild (desonide) corticosteroid ointments were applied on the trunk and the face respectively while docetaxel was maintained. At one month follow-up, the condition improved but without complete clearance. He developed nail onycholysis. The patient responded well to the chemotherapy with an improvement of the metastatic lesions and a drop of PSA levels but docetaxel had to be stopped because of the...
N. Kluger, L. Rentola, P. Hervonen, K. Lappalainen

**Letter to the editor**

N. Kluger, L. Rentola, P. Hervonen, K. Lappalainen

**Figure 2**

Biopsy specimen of the upper back showing showing parakeratosis, dyskeratotic keratinocytes with increased mitoses and solar elastosis in the dermis (hematoxylin-eosin, × 400)

accumulation of side effects such as alopecia, onycholysis, edema of the lower limbs and peripheral neuropathy.

**Discussion**

The inflammation of AK from systemic chemotherapy is a long time known phenomenon [3], albeit not frequently reported [1]. It has mainly been described with 5-fluorouracil or its prodrug (capecitabine) [4,5]. Other systemic drugs (cisplatin, dactinomycin, doxorubicin, vincristine, pemetrexed [6], bendamustine [7]) have been involved, even though in case of polychemotherapy, it can be challenging to assess which drug is the culprit. To our knowledge, docetaxel has been reported only on one prior occasion [8]. However, in this case, docetaxel was administrated with carboplatin. Inflammation of AK has been observed with targeted therapies such as sorafenib [9], erlotinib [10], and panitumumab [11]. As noted by Johnson et al. [1] and as illustrated in our case, AK are usually not clinically apparent before chemotherapy. The physiopathogeny of this local inflammation relies on the DNA synthesis abnormalities that characterize any AK [12]. Thus, they are more like to react to local inflammation. The occurrence of inflamed AK after docetaxel alone. The occurrence of inflamed AK is not an indicator of any drug allergy and should not be an indication for chemotherapy withdrawal.

**References**


Nicolas Kluger1, Leena Rentola2, Petteri Hervonen2, Katriina Lappalainen2

1University of Helsinki, Helsinki University Central Hospital, Departments of dermatology, allergology and venereology, Meilahdentie 2, PO Box 160, 00029 Helsinki, Finland
2Department of Uro-Oncology, Helsinki Comprehensive Cancer Centre, Haartmaninkatu 4, 00029 Helsinki, Finland

Correspondence: Nicolas Kluger, University of Helsinki, Helsinki University Central Hospital, Departments of dermatology, allergology and venereology, Meilahdentie 2, PO Box 160, 00029 Helsinki, Finland

nicolas.kluger@hus.fi

Received 27 December 2017
Accepted 31 January 2018
Available online: https://doi.org/10.1016/j.lpm.2018.01.023

© 2018 Elsevier Masson SAS. All rights reserved.